Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 115Terminated 24Recruiting 14Unknown 8Active not recruiting 7Withdrawn 5Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Neoplasms 35Breast Neoplasms 31Prostatic Neoplasms 22Colorectal Neoplasms 21Leukemia, Myeloid, Acute 19Pancreatic Neoplasms 17Melanoma 17Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 15Lung Neoplasms 13Brain Neoplasms 13Glioma 12Carcinoma, Hepatocellular 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Ovarian Neoplasms 10Myelodysplastic Syndromes 10Multiple Myeloma 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Carcinoma, Renal Cell 8Leukemia 7Sarcoma 6Rectal Neoplasms 6Hematologic Neoplasms 6Esophageal Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5

Interventions

iadademstat 1decitabine and cedazuridine drug combination 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × Myelodysplastic-Myeloproliferative Diseases × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡